|
1
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors - definition, clinical, histological,
immunohistochemical, and molecular genetic features and
differential diagnosis. Virchows Arch. 438:1–12. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-Function Mutations of c-kit in Human
Gastrointestinal Stromal Tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Corless CL and Heinrich MC: Molecular
Pathobiology of Gastrointestinal Stromal Sarcomas. Annu Rev Pathol
Mech Dis. 3:557–586. 2008. View Article : Google Scholar
|
|
4
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: Pathology and prognosis at different sites. Semin
Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duensing A, Medeiros F, McConarty B,
Joseph NE, Panigrahy D, Singer S, Fletcher CDM, Demetri GD and
Fletcher JA: Mechanisms of oncogenic KIT signal transduction in
primary gastrointestinal stromal tumors (GISTs). Oncogene.
23:3999–4006. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miettinen M and Lasota J: Gastrointestinal
Stromal Tumors Review on Morphology, Molecular Pathology,
Prognosis, and Differential Diagnosis. Arch Pathol Lab Med.
130:1466–1478. 2006.PubMed/NCBI
|
|
7
|
Heinrich MC, Rubin BP, Longley BJ and
Fletcher JA: Biology and genetic aspects of gastrointestinal
stromal tumors: KIT activation and cytogenetic alterations. Hum
Pathol. 33:484–495. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corless CL, Fletcher JA and Heinrich MC:
Biology of gastrointestinal stromal tumors. J Clin Oncol.
22:3813–3825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miettinen M, El-Rifai W, H L Sobin L and
Lasota J: Evaluation of malignancy and prognosis of
gastrointestinal stromal tumors: A review. Hum Pathol. 33:478–483.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lasota J and Miettinen M: Clinical
significance of oncogenic KIT and PDGFRA mutations in
gastrointestinal stromal tumours. Histopathology. 53:245–266. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Heinrich MC, Corless CL, Duensing A,
McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A,
Town A, et al: PDGFRA activating mutations in gastrointestinal
stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Corless CL, Schroeder A, Griffith D, Town
A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J and
Heinrich MC: PDGFRA mutations in gastrointestinal stromal tumors:
Frequency, spectrum and in vitro sensitivity to imatinib. J Clin
Oncol. 23:5357–5364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Corless CL, Barnett CM and Heinrich MC:
Gastrointestinal stromal tumours: Origin and molecular oncology.
Nat Rev Cancer. 11:865–878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Joensuu H, Hohenberger P and Corless CL:
Gastrointestinal stromal tumour. Lancet. 382:973–983. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Daniels M, Lurkin I, Pauli R, Erbstösser
E, Hildebrandt U, Hellwig K, Zschille U, Lüders P, Krüger G, Knolle
J, et al: Spectr um of KIT/PDGF RA/BRAF mutations and
Phosphatidylinositol-3-Kinase pathway gene alterations in
gastro-intestinal stromal tumors (GIST). Cancer Lett. 312:43–54.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miranda C, Nucifora M, Molinari F, Conca
E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S,
Pierotti MA, et al: KRAS and BRAF mutations predict primary
resistance to imatinib in gastrointestinal stromal tumors. Clin
Cancer Res. 18:1769–1776. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pantaleo MA, Nannini M, Corless CL and
Heinrich MC: Quadruple wild-type (WT) GIST: Defining the subset of
GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling
pathways. Cancer Med. 4:101–103. 2015. View Article : Google Scholar :
|
|
18
|
Lasota J, Felisiak-Golabek A, Wasag B,
Kowalik A, Zięba S, Chłopek M, Wang ZF, Coates T, Kopczynski J,
Gozdz S, et al: Frequency and clinicopathologic profile of PIK3CA
mutant GISTs: Molecular genetic study of 529 cases. Mod Pathol.
29:275–282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Drilon A, Laetsch TW, Kummar S, DuBois SG,
Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo
AS, et al: Efficacy of larotrectinib in TRK fusion-positive cancers
in adults and children. N Engl J Med. 378:731–739. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Isozaki K and Hirota S: Gain-of-Function
Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal
Tumors. Curr Genomics. 7:469–475. 2006. View Article : Google Scholar
|
|
21
|
Nishida T, Takahashi T and Miyazaki Y:
Gastrointestinal stromal tumor: A bridge between bench and bedside.
Gastric Cancer. 12:175–188. 2009. View Article : Google Scholar
|
|
22
|
Fletcher JA and Rubin BP: KIT mutations in
GIST. Curr Opin Genet Dev. 17:3–7. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gramza AW, Corless CL and Heinrich MC:
Resistance to tyrosine kinase inhibitors in gastrointestinal
stromal tumors. Clin Cancer Res. 15:7510–7518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Origone P, Gargiulo S, Mastracci L,
Ballestrero A, Battistuzzi L, Casella C, Comandini D, Cusano R, Dei
Tos AP, Fiocca R, et al Liguria GIST Unit: Molecular
characterization of an Italian series of sporadic GISTs. Gastric
Cancer. 16:596–601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Penzel R, Aulmann S, Moock M, Schwarzbach
M, Rieker RJ and Mechtersheimer G: The location of KIT and PDGFRA
gene mutations in gastrointestinal stromal tumours is site and
phenotype associated. J Clin Pathol. 58:634–639. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wozniak A, Rutkowski P, Schöffski P,
Ray-Coquard I, Hostein I, Schildhaus HU, Le Cesne A, Bylina E,
Limon J, Blay JY, et al: Tumor genotype is an independent
prognostic factor in primary gastrointestinal stromal tumors of
gastric origin: A european multicenter analysis based on
ConticaGIST. Clin Cancer Res. 20:6105–6116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Emile JF, Brahimi S, Coindre JM, Bringuier
PP, Monges G, Samb P, Doucet L, Hostein I, Landi B, Buisine MP, et
al: Frequencies of KIT and PDGFRA mutations in the MolecGIST
prospective population-based study differ from those of advanced
GISTs. Med Oncol. 29:1765–1772. 2012. View Article : Google Scholar
|
|
28
|
Debiec-Rychter M, Sciot R, Le Cesne A,
Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S,
Stul M, Casali PG, et al EORTC Soft Tissue and Bone Sarcoma Group;
Italian Sarcoma Group; Australasian GastroIntestinal Trials Group:
KIT mutations and dose selection for imatinib in patients with
advanced gastrointestinal stromal tumours. Eur J Cancer.
42:1093–1103. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heinrich MC, Owzar K, Corless CL, Hollis
D, Borden EC, Fletcher CDM, Ryan CW, Von Mehren M, Blanke CD,
Rankin C, et al: Correlation of kinase genotype and clinical
outcome in the North American intergroup phase III trial of
imatinib mesylate for treatment of advanced gastrointestinal
stromal tumor: CALGB 150105 study by cancer and leukemia group B
and southwest oncology gr. J Clin Oncol. 26:5360–5367. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Andersson J, Bümming P, Meis-Kindblom JM,
Sihto H, Nupponen N, Joensuu H, Odén A, Gustavsson B, Kindblom L-G
and Nilsson B: Gastrointestinal stromal tumors with KIT exon 11
deletions are associated with poor prognosis. Gastroenterology.
130:1573–1581. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boikos SA, Pappo AS, Killian JK, LaQuaglia
MP, Weldon CB, George S, Trent JC, von Mehren M, Wright JA,
Schiffman JD, et al: Molecular Subtypes of KIT/PDGFRAWild-Type
Gastrointestinal Stromal Tumors. JAMA Oncol. 2:9222016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huss S, Pasternack H, Ihle MA,
Merkelbach-Bruse S, Heitkötter B, Hartmann W, Trautmann M,
Gevensleben H, Büttner R, Schildhaus HU, et al: Clinicopathological
and molecular features of a large cohort of gastrointestinal
stromal tumors (GISTs) and review of the literature: BRAF mutations
in KIT/PDGFRA wild-type GISTs are rare events. Hum Pathol.
62:206–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shi SS, Wu N, He Y, Wei X, Xia QY, Wang X,
Ye S, Li R, Rao Q and Zhou X-J: Bin, Li R, Rao Q and Zhou XJ: EGFR
gene mutation in gastrointestinal stromal tumours. Histopathology.
71:553–561. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nakahara M, Isozaki K, Hirota S, Miyagawa
J, Hase-Sawada N, Taniguchi M, Nishida T, Kanayama S, Kitamura Y
and Shinomura Y: A novel gain-of-function mutation of c-kit gene in
gastrointestinal stromal tumors. Gastroenterology. 115:1090–1095.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lasota J, Jasinski M, Sarlomo-Rikala M and
Miettinen M: Mutations in exon 11 of c-Kit occur preferentially in
malignant versus benign gastrointestinal stromal tumors and do not
occur in leiomyomas or leiomyosarcomas. Am J Pathol. 154:53–60.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Taniguchi M, Nishida T, Hirota S, Isozaki
K, Ito T, Nomura T, Matsuda H and Kitamura Y: Effect of c-kit
mutation on prognosis of gastrointestinal stromal tumors. Cancer
Res. 59:4297–4300. 1999.PubMed/NCBI
|
|
37
|
Moskaluk CA, Tian Q, Marshall CR, Rumpel
CA, Franquemont DW and Frierson HF Jr: Mutations of c-kit JM domain
are found in a minority of human gastrointestinal stromal tumors.
Oncogene. 18:1897–1902. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wardelmann E, Losen I, Hans V, Neidt I,
Speidel N, Bierhoff E, Heinicke T, Pietsch T, Büttner R and
Merkelbach-Bruse S: Deletion of Trp-557 and Lys-558 in the
juxtamembrane domain of the c-kit protooncogene is associated with
metastatic behavior of gastrointestinal stromal tumors. Int J
Cancer. 106:887–895. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Martín-Broto J, Rubio L, Alemany R and
López-Guerrero JA: Clinical implications of KIT and PDGFRA
genotyping in GIST. Clin Transl Oncol. 12:670–676. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Van Glabbeke M; Gastrointestinal Stromal
Tumor Meta-Analysis Group (MetaGIST): Comparison of two doses of
imatinib for the treatment of unresectable or metastatic
gastrointestinal stromal tumors: A meta-analysis of 1,640 patients.
J Clin Oncol. 28:1247–1253. 2010. View Article : Google Scholar
|
|
41
|
Lasota J and Miettinen M: KIT and PDGFRA
mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn
Pathol. 23:91–102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Conca E, Miranda C, Dal Col V, Fumagalli
E, Pelosi G, Mazzoni M, Fermeglia M, Laurini E, Pierotti MA,
Pilotti S, et al: Are two better than one? A novel double-mutant
KIT in GIST that responds to Imatinib. Mol Oncol. 7:756–762. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pai T, Bal M, Shetty O, Gurav M, Ostwal V,
Ramaswamy A, Ramadwar M and Desai S: Unraveling the spectrum of KIT
mutations in gastrointestinal stromal tumors: An Indian Tertiary
Cancer Center Experience. South Asian J Cancer. 6:113–117. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Serrano C, Mariño-Enríquez A, Tao DL,
Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD,
et al: Complementary activity of tyrosine kinase inhibitors against
secondary kit mutations in imatinib-resistant gastrointestinal
stromal tumours. Br J Cancer. 120:612–620. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang CM, Huang K, Zhou Y, Du CY, Ye YW, Fu
H, Zhou XY and Shi YQ: Molecular mechanisms of secondary imatinib
resistance in patients with gastrointestinal stromal tumors. J
Cancer Res Clin Oncol. 136:1065–1071. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gajiwala KS, Wu JC, Christensen J,
Deshmukh GD, Diehl W, Dinitto JP, English JM, Greig MJ, He Y-A,
Jacques SL, et al: KIT kinase mutants show unique mechanisms of
drug resistance to imatinib and sunitinib in gastrointestinal
stromal tumor patients. Proc Natl Acad Sci U S A. 106:1542–1547.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mol CD, Dougan DR, Schneider TR, Skene RJ,
Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC and Wilson KP:
Structural basis for the autoinhibition and STI-571 inhibition of
c-Kit tyrosine kinase. J Biol Chem. 279:31655–31663. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Roskoski R Jr: Structure and regulation of
Kit protein-tyrosine kinase - the stem cell factor receptor.
Biochem Biophys Res Commun. 338:1307–1315. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bachet JB, Hostein I, Le Cesne A, Brahimi
S, Beauchet A, Tabone-Eglinger S, Subra F, Bui B, Duffaud F,
Terrier P, et al: Prognosis and predictive value of KIT exon 11
deletion in GISTs. Br J Cancer. 101:7–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Garner AP, Gozgit JM, Anjum R, Vodala S,
Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, et al:
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and
shows thera-peutic potential in heavily pretreated gastrointestinal
stromal tumor (GIST) patients. Clin Cancer Res. 20:5745–5755. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang HC, Li TY, Chao YJ, Hou YC, Hsueh YS,
Hsu KH and Shan YS: Kit exon 11 codons 557-558 deletion mutation
promotes liver metastasis through the CXCL12/CXCR4 Axis in
gastroin-/CXCR4 Axis in gastroin CXCR4 Axis in gastroin--testinal
stromal tumors. Clin Cancer Res. 22:3477–3487. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wozniak A, Rutkowski P, Piskorz A,
Ciwoniuk M, Osuch C, Bylina E, Sygut J, Chosia M, Rys J, Urbanczyk
K, et al Polish Clinical GIST Registry: Prognostic value of
KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST):
Polish Clinical GIST Registry experience. Ann Oncol. 23:353–360.
2012. View Article : Google Scholar
|
|
53
|
Lasota J, Wasag B, Steigen SE, Limon J and
Miettinen M: Improved detection of KIT exon 11 duplications in
formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.
J Mol Diagn. 9:89–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
